Alnylam Pharma(ALNY.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Alnylam Pharma
ALNY.US
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections.
1.820 T
ALNY.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
BiotechnologyIndustry
Industry Ranking10/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE90.36%A
    • Profit Margin12.55%B
    • Gross Margin81.91%A
  • Growth ScoreA
    • Revenue YoY82.57%A
    • Net Profit YoY333.43%A
    • Total Assets YoY21.73%A
    • Net Assets YoY831.59%A
  • Cash ScoreB
    • Cash Flow Margin132.88%B
    • OCF YoY82.57%A
  • Operating ScoreA
    • Turnover0.92A
  • Debt ScoreE
    • Gearing Ratio79.04%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

    Market Beat·
    US
    ALNY
    +2.81%
    US
    FBT
    +0.54%
    US
    LABU
    -2.35%
    Market Beat·
    US
    ALNY
    +2.81%
    US
    FBT
    +0.54%
    US
    LABU
    -2.35%

    New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden | ALNY Stock News

    StockTitan·
    US
    ALNY
    +2.81%
    US
    XLV
    +1.10%
    US
    VHT
    +0.97%
    StockTitan·
    US
    ALNY
    +2.81%
    US
    XLV
    +1.10%
    US
    VHT
    +0.97%

    Alnylam rebuked by FDA over efficacy claims on Amvuttra website

    Fiercepharma·
    US
    ALNY
    +2.81%
    US
    TBXU
    +2.01%
    US
    XLV
    +1.10%
    Fiercepharma·
    US
    ALNY
    +2.81%
    US
    TBXU
    +2.01%
    US
    XLV
    +1.10%

    Pre-market hot trades in US stocks: Alnylam Pharma up 9.59% pre-market; Biodexa Pharmaceuticals down 9.38% pre-market

    Price Alert·
    US
    ALNY
    +2.81%
    US
    BDRX
    -0.63%
    Price Alert·
    US
    ALNY
    +2.81%
    US
    BDRX
    -0.63%

    Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

    Market Beat·
    US
    ALNY
    +2.81%
    US
    FBT
    +0.54%
    US
    BIB
    +0.05%
    Market Beat·
    US
    ALNY
    +2.81%
    US
    FBT
    +0.54%
    US
    BIB
    +0.05%
    © 2026 Longbridge｜Disclaimer